The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Additional Listing

3 Feb 2020 12:00

RNS Number : 6333B
Consort Medical PLC
03 February 2020
 

 

 

 

3 February 2020

 

Consort Medical plc ("the Company")

 

 

Additional listing

 

Application has been made to the UK Listing Authority and the London Stock Exchange for a listing of 366,863 Ordinary Shares of 10 pence each ("Shares") to be admitted to the Official List. The Shares are to be issued to satisfy the exercise of options under the Company's 2015 Performance Share Plans, and the listing relates to the balance of Shares not available to be drawndown under the Company's existing block listings in place for the plan.

The Shares will rank pari passu with the existing issued Ordinary Shares of the Company, and it is expected that admission to trading in the Shares will become effective on 4 February 2020.

Following the issue of the Shares, the Company will have 49,731,097 Ordinary shares in issue. There are no shares held in treasury.

 

 

 

 

Enquiries: 

Consort Medical

Tel: +44 (0) 1442 867920

Andrew Jackson - Group Counsel and Company Secretary

 

About Consort Medical plc

 

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses:

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ approximately 2,000 people globally of which approximately 1,400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSKZGFMKMMGGZM

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.